WSJournal - How Psychiatry Went Crazy The "bible" of

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone

WSJournal - How Psychiatry Went Crazy

The "bible" of psychiatric diagnosis shapes—and deforms—both treatment and policy.

The Diagnostic and Statistical Manual of Mental Disorders is often called the "Bible" of psychiatric diagnosis, and the term is apt. The DSM consists of instructions from on high; readers usually disagree in their interpretations of the text; and believing it is an act of faith.

At least the Bible lists only 10 Commandments; the DSM grows by leaps and bounds with every revision. The first edition, published by the American Psychiatric Association in 1952, was a spiral-bound pamphlet that described 11 categories of mental disorder, including brain syndromes, personality problems and psychotic disorders. (The final category, "Nondiagnostic Terms for the Hospital Record," contained Dead on Admission, the one diagnosis that psychiatrists have ever agreed on.) The DSM-II (1968) made homosexuality a mental disorder, a decision revoked by vote in 1973. In the general excitement about that progressive decision, few noted that voting didn't seem to be the most scientific way of determining mental illness . Narcissistic Personality Disorder was voted out in 1968 and voted back in 1980; where did it go for 12 years? Doctors don't vote on whether pneumonia is a disease.

The DSM-III (1980) was an effort to jettison outdated theories and terms such as "neurosis" and replace them with an objective list of disorders with agreed-upon symptoms. The DSM-IIIR (1987) was 567 pages and included nearly 300 disorders. The DSM-IV (1994, slightly revised in 2000) was 900 pages and contained nearly 400 disorders. The new DSM-5, with its modernized Arabic number, is 947 pages. It contains, along with serious mental illnesses, "binge-eating disorder" (whose symptoms include "eating when not feeling physically hungry"), "caffeine intoxication," "parent-child relational problem" and my favorite, "antidepressant discontinuation syndrome." Now psychiatrists can treat the symptoms of going off antidepressants, which is good because the expanded criteria for many disorders allows doctors to prescribe antidepressants more often for more problems. Gone is the "bereavement exemption," for example. You used to get two weeks after a loved one died before you could be diagnosed with major depression and medicated. Now you get two minutes.

If people treated the DSM the way most treat the other Bible—nod their heads to it, say they believe in it and continue sinning—we might be all right. Many psychotherapists who still practice therapy, rather than prescribe a cocktail of Zoloft and Risperdal with a tincture of Ritalin, do just that. They find a label that suits, for insurance purposes, and then get on with helping the client.

But the DSM has grown too powerful to ignore; it is the linchpin of the pharmaceutical-medical complex. Adding more disorders allows doctors to be compensated for treating any kind of problem, from garden-variety sorrow to incapacitating depression. Drug companies encourage new disorders so that they can create medications or repackage old ones: Prozac, when its patent expired, was renamed Sarafem to treat "Premenstrual Dysphoric Disorder." PMDD had been relegated to the kids' table (that is, an appendix) in the DSM-IV, thanks to protests by women clinicians who wondered why menstrual symptoms constitute a "mental disorder" when, say, Hypertestosterone Hostility Disorder is nowhere to be found. Alas, PMDD has moved to the adults' table in the DSM-5. HHD is still MIA.

Criticism of the DSM began to coalesce in the 1990s, with Stuart Kirk and Herb Kutchins's "The Selling of DSM" (1992) and "Making Us Crazy" (1997), as well as Paula Caplan's "They Say You're Crazy" (1996). Now, Gary Greenberg, a psychotherapist and the author of "Manufacturing Depression" (2010), and Allen Frances, a psychiatrist who was task-force chair of the revision of the fourth DSM, have joined the chorus of critics. Their books share the goal of skewering the pretensions of the latest revision and using what is wrong about the DSM to remind us of what diagnosis and therapy should be for. But they diverge in one crucial way: Dr. Frances is sitting on the fence about what the DSM's power means for psychiatry; Mr. Greenberg has leapt over it.

In "The Book of Woe," Mr. Greenberg takes us on a rollicking journey from the DSM-5's inception to its publication, regaling us with stories, alternately hilarious and infuriating, of internecine battles, personality clashes and political machinations. Mr. Greenberg is an outsider by virtue of not being a psychiatrist but an insider by virtue of serving as one of the investigators involved in field-testing some proposed diagnoses on actual patients. He interviewed the major players; he watched as feathers were ruffled and smoothed; he attended conferences, documenting with growing disbelief the failures of the American Psychiatric Association's task forces to produce the scientific results they had aimed for.

And he was there when those scientific aspirations met reality and all hell broke loose. Mr. Greenberg gives us a front-row seat at the APA's annual meeting in 2011, when results of the field trials were reported. Field trials are intended to test the reliability of diagnostic criteria—meaning that two psychiatrists observing the same person's symptoms should have a pretty good chance of agreeing on a diagnosis. But the results were dismal. Agreement on identifying even Major Depressive Disorder and Generalized Anxiety Disorder—what Mr. Greenberg calls the "Dodge Dart and Ford Falcon of the DSM, simple and reliable and ubiquitous" disorders—was low. Moreover, the field testing on patients failed miserably: 5,000 clinicians signed up to participate, 195 finished training for it, and only 70 enrolled any patients in trials. The APA tried to put a good spin on these numbers —"nearly 150 patients have joined the study"—ignoring, Mr. Greenberg notes, that their goal was 10,000. Only two months before the data had to be in, the clinician field trials had barely begun.

Why would the APA rush publication in spite of unfinished field trials and failures to find high reliability among clinicians, the very things that their claims to a scientific DSM rely on? Do the math, Mr. Greenberg answers. In recent years, the APA has been steadily losing income from dwindling membership and dwindling ad revenues for its journals. The DSM-IV, which has earned $100 million, keeps the organization in the black. Faced with a looming deadline and terrible data, Mr. Greenberg suggests, the DSM directors did what any reasonable, self-protecting institution would do: They lowered the statistical criteria for acceptable standards of reliability and turned defeat into victory. As Allen Frances puts it in "Saving Normal," they accepted agreements among raters that were "sometimes barely better than two monkeys throwing darts at a diagnostic board."

I encountered Allen Frances in the pages of Mr. Greenberg's book before I read his own. Mr. Greenberg's conversations, emails, and debates with Dr. Frances are woven through his narrative, and Dr. Frances emerges as funny, furious, defensive and courageous. Allies and adversaries, they never agree on whether criticizing the DSM is good for psychiatry or bad. Mr. Greenberg wonders whether he is helping to undermine a profession "that offers the last and only hope for some patients" with psychosis and other severe disorders. But he concludes that the truth needs to be told: Even in the hands of "honest and eloquent men" such as Dr. Frances, he writes, "psychiatric diagnosis is built on fiction and sold to the public as fact."

Dr. Frances can't go that far. "My critique," he makes sure we know, "is directed only against the excesses of psychiatry, not its heart or soul." In conversations with Mr. Greenberg, he worries that his words will be misused "by the antipsychiatry fanatics" who oppose psychiatric diagnosis and treatment altogether. "The field is a lot better," he says, "than anyone would assume watching the DSM-5 follies unfold."

Accordingly, in "Saving Normal," Dr. Frances attempts the delicate task of debunking the DSM-5 while justifying his own DSM-IV. He was alarmed by the DSM-5's proposals of "new diagnoses that would turn everyday anxiety, eccentricity, forgetting, and bad eating habits into mental disorders." His 6-year-old twin grandsons wouldn't have tantrums any more but "disruptive mood dysregulation disorder," and his own normal forgetting of names and faces would be "mild neurocognitive disorder." Yet the DSM-IV gave us a Disorder of Written Expression, Caffeine-Induced Sleep Disorder and Age-related Cognitive Decline, all of which I suffer on every deadline.

Dr. Frances describes his book as "part mea culpa, part j'accuse, part cri de coeur." The mea culpa is admirable but also gives him the greatest difficulty. When he was at the helm, he contends, pet proposals were "consistently shot down" if the science wasn't there to support them. The DSM-IV committees were "boringly modest in our goals, obsessively meticulous in our methods, and rigidly conservative in our product." "Methodological rigor," he claims, was their hallmark, even as he acknowledges that "all of our diagnoses are now based on subjective judgments that are inherently fallible and prey to capricious change." It wasn't the DSM-IV's fault that it did not prevent "the rampant diagnostic inflating" or the "national drug overdose of medication" that followed its publication. The framers of the DSM-IV were, at worst, "naïve" in failing to worry that 56% of their experts had financial ties to drug companies.

Dr. Frances repeatedly chastises the writers of the DSM-5 for failing to ask Hippocrates' question: Will this new diagnosis help patients or harm them? But the DSM-IV failed to ask the same question when, for example, it retained Multiple Personality Disorder. After the DSM-III included MPD in 1980, thousands of spurious cases emerged in the next two decades, and special psychiatric clinics arose to treat them. Yet faced with evidence of this disastrous epidemic, the DSM-IV did not delete the diagnosis. Instead, the manual renamed it Dissociative Identity Disorder. "MPD presented a dilemma for me," Dr. Frances says. "We took scrupulous pains to present both sides of the controversy as fairly and effectively as possible—even though I believed one side was complete bunk." How do you "fairly" argue for a diagnosis you think is complete bunk? Where's the methodological rigor? Why did it take malpractice suits to close the psychiatric MPD clinics and not the presumed voice of scientific authority, the DSM? Dissociative Identity Disorder remains in the DSM-5.

Nonetheless, Dr. Frances does his best to save psychiatry. It is impossible to define "normal," he explains, let alone "mental disorder." But that doesn't mean, he adds, that we can't talk about the problems that cause human suffering. Mental disorders should be diagnosed only when a person's symptoms are obvious, severe and haven't gone away on their own. Watchful waiting should be the first step in treatment, and medication a last resort. A wise, and increasingly rare, approach.

Is there another way to classify mental problems? The National Institute of Mental Health has washed its hands of the DSM and is working on its own system for 2020. As NIMH director Thomas Insel pronounced: "Mental disorders are biological disorders involving brain circuits that implicate specific domains of cognition, emotion, or behavior." A NIMH initiative plans to produce "precision medicine" to treat them.

Don't hold your breath, though. Readers of both "The Book of Woe" and "Saving Normal" will learn why the goal of "precision medicine" in mental health is a mirage. The DSM committees already tried their damnedest to support their diagnoses with neuroscience or biomarkers, but no lab tests yet exist for depression, schizophrenia, bipolar or obsessive-compulsive disorder, or, for that matter, any other mental disorders. Efforts to find explanations in genes, neurotransmitters, "chemical imbalances" or brain circuits have, Dr. Frances writes, "turned out to be naïve and illusory."

But, oh, the yearning for simple-minded (so to speak) brain measures of disorder. After years of wandering in the "biomedical desert," Mr. Greenberg writes, how happy psychiatrists will be to reach the promised land, where they will not have to talk to patients at all, just scan their brains with a costly fMRI! "When the DSM is finally full of words like nucleus accumbens and putamen ," says Mr. Greenberg, critics like him will be out of business.

I hope not; we will need them more than ever. The dream of biomedical markers may prove as fruitless as the dream of a scientific DSM: Both try to "pour the old wine of human suffering into the new skin of scientific medicine," Mr. Greenberg writes. Fortunately for us, he concludes, the human mind "has so far resisted this attempt to turn its discontents into a catalog of suffering. And for this we should be glad."

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiofrequency Microneedling: A Fresh Skin Solution?

Updated Category News Views 106

Vet the Process Before Diving In Everyone wants to turn back the clock on their skin, but it's crucial to know what you're getting into. This ain't a quick splash of water on the face; it's radiofrequency microneedling we're talking about. And honey, it’s no fairy tale—it’s science, plain and simple. Drilling Down on Microneedling This procedure, preached by Dr....

Continue Reading
BlazeSports Marks 30 Years at Awards Gala Celebration

Updated Category News Views 45

Thirty Years of Empowering Athletes In the world of adaptive sports, every slam dunk and sprint finish means more than just a win; it signifies victory over barriers that many of us can't even fathom. That's the world BlazeSports America has championed for three decades now. And let me tell you, not every organization has what it takes to stick it out this long,...

Continue Reading
Neuberger Fund Ups Distribution Amid Market Challenges

Updated Category News Views 56

Neuberger Boosts Distribution: What's Driving This? I ain't about to sugarcoat it: the Neuberger Next Generation Connectivity Fund (NYSE: NBXG) decided to jack up its monthly distribution rate to $0.132 per share. This announcement, hitting wallets on November 30, 2026, has a record and ex-date of November 16. Now, that's a good ol' reliable payout for folks holding NBXG...

Continue Reading
Winter Travel Booms: Top Destinations Unveiled for 2026

Updated Category News Views 121

Winter Travel Surge: Rising Demand for Top Destinations Every year as the temperature drops, the excitement for winter travel heats up, and this season's no different. Booking patterns confirm that while people are dreaming of holiday magic, they're also gunning for sun when cold's on the horizon. New York City's holiday glitz leads the domestic charge, backed by a power...

Continue Reading
Highway Motors Deal Reflects Shifts in Auto Trade

Updated Category News Views 37

A Family Legacy Transitions in Virginia The trucking world doesn't stop spinning, and Highway Motors, an International dealer rooted deep in Virginia's soil since 1929, knows this intimately. This isn't just a back-of-the-napkin sale; it's a strategic move sweeping through the Interstate 81 corridor, touching Winchester, Harrisonburg, Roanoke, and Leesburg locales. What...

Continue Reading
Sentral Expands: Fort Lauderdale & San Diego Additions

Updated Category News Views 173

Sentral's Strategic Leap into New Markets Ever heard of a company spreading its wings like wildfire? That’s Sentral for you, crashing into Fort Lauderdale and pushing deeper roots in San Diego. We’re not talking minor plays here—these two fresh additions make Sentral a resident-giant stretched across 22 markets. Seems like they’re on a mission to ink their mark...

Continue Reading
Sodium-Ion Tech Showcased by Aeson Power in Melbourne

Updated Category News Views 164

A Shock to the System: Sodium-Ion's Rising Star If you're tired of hearing about lithium, Aeson Power just gave us a much-needed jolt at All Energy Australia 2026. This isn't just some new fad—they've proven the real-world chops of sodium-ion technology across energy storage and automotive platforms. At the Melbourne show, they laid out their goods, showing how this...

Continue Reading
Z Squared Eyes 150 MW Expansion at Arkansas Site

Updated Category News Views 48

Turning Power into Potential at Union County Next stop, Union County, Arkansas. Z Squared Inc. (Nasdaq: ZSQR) isn't just talking shop; they're getting down to work. With a freshly acquired site through Paradox Data, LLC, Z Squared's planning to turn vision into reality. The site's already armed with 8 MW of juice, all ready to roll, but their ambitions shoot up to 150 MW...

Continue Reading
Loomis Reports Record Revenue Amid Strong Q3 Growth

Updated Category News Views 23

Impressive Gains in a Competitive Sphere You ever seen a stock jump like it's got springs in its heels? That's Loomis for you, rocking the third quarter with record-breaking numbers. The revenue clocked in at a cool SEK 8,161 million, shooting past last year’s by more than half a billion. Toss in a 15.1% EBITA margin, and you’re looking at a company flexing some real...

Continue Reading
Food Emulsifiers Surge: Market to Hit $5.60B by 2031

Updated Category News Views 72

Forecasting Growth in Food Emulsifiers Picture this: the food emulsifiers market is steaming ahead, anticipating a thunderous boom from $4.43 billion in 2026 to a whopping $5.60 billion by 2031. According to recent estimates, that's a steady clip at a CAGR of 4.8%. If you're thinking that's just more industry chatter, let's peel back the layers and see what makes this...

Continue Reading

Top 5 Most Recently Viewed Articles

HD Hyundai Partners with U.S. Firm to Boost Shipbuilding Efforts

Updated Category News Views 639

HD Hyundai and Tampa Ship Collaboration Overview In an exciting move for the maritime industry, HD Hyundai has entered into an exclusive Memorandum of Understanding (MOU) with Tampa Ship, which belongs to the Edison Chouest Offshore family. This strategic collaboration aims to enhance commercial shipbuilding capacity within the United States. Goals of the Shipbuilding...

Continue Reading
Celebrating Generosity: FASTPORT and Tenstreet's Dedication

Updated Category News Views 169

Supporting Wreaths Across America: A Commitment to Honor COLUMBIA FALLS, Maine and ARLINGTON, Va. – Wreaths Across America (WAA) proudly announces that title sponsors FASTPORT and Tenstreet are returning to support the annual Appreciation Dinner and Rally. This special event is scheduled for the eve of National Wreaths Across America Day, focusing on honoring the...

Continue Reading
Enersponse's Remarkable Achievements Fuel Future Growth

Updated Category News Views 191

Celebrating a Year of Achievements at Enersponse Enersponse, a distributed energy resource management provider and Virtual Power Plant (VPP) operator, has wrapped up a remarkable year showcasing significant accomplishments that advance its mission to create a flexible, reliable, and resilient electrical grid. The company experienced stellar growth in recent months,...

Continue Reading
Hanson Builders Launches St. Jude Dream Home in Minnesota

Updated Category News Views 452

Hanson Builders Launches a Community Project in Minnesota Hanson Builders, a prominent home construction company, is excited to have broken ground on the first St. Jude Dream Home Showplace in Minnesota. With an unwavering dedication to community service, this initiative is set to play an essential role in supporting children who are battling serious health challenges....

Continue Reading
Timken Company Investor Conferences for Growth and Insight

Updated Category News Views 131

Timken Company Invites Investors to Upcoming Events The Timken Company (NYSE: TKR), recognized globally for its engineering excellence in bearings and industrial motion, is gearing up for two significant investor conferences. These events will take place in New York City, showcasing the company's commitment to engaging with its investors. Details of the Upcoming...

Continue Reading